TMDX Company Profile and Key Details

TMDX has shown sold momentum, gaining 5.4% over the past week and 20.66% over the past quarter, though year-to-date performance is up 16.67%. Short-term trend indicators are bearishly aligned (SMA20 0.42%, SMA50 1.3%, SMA200 7.31%). The stock’s 14-day RSI is 50.39 (neutral), while the ATR of 7.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -13.74% below its high and over 116.79% above its low. Average 10-day trading volume of 810.66 thousand shares is in line with the 3-month average of 899.63 thousand, indicating normal recent market interest.

TransMedics Group, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.09. This means the shares are trading below this model’s fair value.

TransMedics Group, Inc. (NASDAQ:TMDX) closed at $110.70 USD, losing -$5.41 (-4.66%) from the previous close of $116.11. The stock is currently mid-range between its 52-week high and low $84.53 and $156.00. With a market capitalization of about $3.80 billion, TransMedics Group, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~2.08). Key stats such as the average daily volume over the past year has been around 891.69 thousand shares, volume is running light vs its 52-week average. Headquartered in Andover, MA, TransMedics Group, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Waleed H. Hassanein, the company employs approximately 728 people and listed since May 02, 2019. TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.

Wall Street analysts project EPS growth of -1.06% annually over the next five years. The latest quarter delivered EPS of $0.66. The next quarter is forecast at $0.66. Next year's EPS is expected at $44.85. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 8 Buy ratings, 5 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $175.00 to $115.00. The high target offers 51.28% upside. The low target suggests -0.59% downside. The mean target is $146.60. This offers 26.73% upside. TransMedics Group, Inc. earnings surprise history is a mixed track record. The quarter that ended October 29, 2025, missed forecasts by 78.38%. The prior quarter beat by 91.67%. Over the last six quarters, Apple has recorded several small beats. These include 66.67% in July 31, 2024.

TransMedics Group, Inc. has 34.09 million shares outstanding. The public float is 32.96 million shares, elevated short interest at 41.68% of float. This equals 8.27 million shares. The short ratio is 7.15 days. Institutional investors hold 114.66% of the float. Insiders own 2.95%. Hassanein Waleed H holds 495.01 thousand shares, TOBIN JAMES R has 173.15 thousand shares and Khayal Tamer I has 36.04 thousand shares. Over the past six months, insider transactions show net selling. They sold 27.94 thousand shares across 10 transactions.

TransMedics Group, Inc. trades at a P/E ratio of 20.66, slightly below the S&P 500 average, with a price-to-sales ratio of 6.51 and a price-to-book ratio of 8.31 trading at moderately above to book value. The P/FCF stands at 29.49, also below market averages.

Our AI price prediction model suggests that TransMedics Group, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.72%, with price expected at $103.28 by April 28, 2026, within a range of $93.73 to $111.52 3-Month Outlook: Projected rise of 19.27%, reaching $137.97 by July 13, 2026, with a range of $127.88 to $150.14. 1-Year Outlook: Projected gain of 22.61%, with price at $141.84 by April 14, 2027, within a range of $133.45 to $152.39.

TransMedics Group, Inc. (NASDAQ:TMDX) shares are up 16.67% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows TransMedics Group, Inc. trading at a premium to the broader market with a P/E of 20.66. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $124.79, suggesting 7.88% upside. Our AI forecast model points to short-term weakness (-10.72% over two weeks), a medium-term rise (19.27% over three months), and a longer-term gain (22.61% over one year), with expected trading ranges indicating moderate volatility.